Patent ID: 7666425
Filing Date: 2010-02-23
Classification: A61K,A61P,C07K,G01N,Y10S

Abstract:
1. A method of treating prostate cancer comprising: providing a monoclonal antibody or antigen binding portion thereof which binds to prostate specific membrane antigen (PSMA) and competes for binding to PSMA with a monoclonal antibody selected from the group consisting of a monoclonal antibody produced by a hybridoma with an ATCC accession number HB-12101, a monoclonal antibody produced by a hybridoma with an ATCC accession number HB-12127, and a monoclonal antibody produced by a hybridoma with an ATCC accession number HB-12126 wherein the antibody or antigen binding portion thereof is conjugated to a cytotoxic drug; and administering the antibody or antigen binding portion thereof to a subject under conditions effective to treat prostate cancer.